ATE411387T1 - Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren - Google Patents
Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahrenInfo
- Publication number
- ATE411387T1 ATE411387T1 AT01933020T AT01933020T ATE411387T1 AT E411387 T1 ATE411387 T1 AT E411387T1 AT 01933020 T AT01933020 T AT 01933020T AT 01933020 T AT01933020 T AT 01933020T AT E411387 T1 ATE411387 T1 AT E411387T1
- Authority
- AT
- Austria
- Prior art keywords
- rabies virus
- human monoclonal
- nucleic acid
- monoclonal antibodies
- related methods
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 206010037742 Rabies Diseases 0.000 title 1
- 241000711798 Rabies lyssavirus Species 0.000 abstract 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 238000009117 preventive therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20451800P | 2000-05-16 | 2000-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411387T1 true ATE411387T1 (de) | 2008-10-15 |
Family
ID=22758233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01933020T ATE411387T1 (de) | 2000-05-16 | 2001-05-04 | Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6890532B2 (de) |
| EP (1) | EP1282703B1 (de) |
| JP (1) | JP4819285B2 (de) |
| AT (1) | ATE411387T1 (de) |
| CA (1) | CA2419148C (de) |
| DE (1) | DE60136174D1 (de) |
| IL (1) | IL152825A (de) |
| RU (1) | RU2272809C2 (de) |
| WO (1) | WO2001088132A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040013672A1 (en) * | 2000-05-16 | 2004-01-22 | Thomas Jefferson University | Recombinant antibodies, and compositions and methods for making and using the same |
| AU2001281151A1 (en) * | 2000-08-24 | 2002-03-04 | Thomas Jefferson University | Rhabdovirus-based vectors to express high levels of functional human antibodies |
| NZ531291A (en) * | 2001-08-21 | 2006-02-24 | Univ Jefferson | Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| CA2965865C (en) | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
| EP2395016A3 (de) | 2003-05-30 | 2012-12-19 | Merus B.V. | Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| DK1737971T3 (da) | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
| PL1851315T3 (pl) * | 2005-02-02 | 2014-06-30 | Univ Massachusetts | Ludzkie przeciwciała przeciwko wściekliźnie i ich zastosowania |
| JP2008263964A (ja) * | 2007-03-29 | 2008-11-06 | Yamaguchi Univ | コウモリ由来細胞株 |
| JP2010085126A (ja) * | 2008-09-29 | 2010-04-15 | Adtec Kk | 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法 |
| KR101388680B1 (ko) * | 2011-03-18 | 2014-04-28 | (주)셀트리온 | 광견병 바이러스를 중화시킬 수 있는 결합 분자 |
| AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
| RU2533802C1 (ru) * | 2013-08-30 | 2014-11-20 | федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства |
| WO2019227039A1 (en) * | 2018-05-24 | 2019-11-28 | Lankenau Institute For Medical Research | Compositions comprising antibodies to rabies virus and the uses thereof |
| CN111166877A (zh) * | 2019-12-30 | 2020-05-19 | 西安回天血液制品有限责任公司 | 一种狂犬病人免疫球蛋白的制备方法 |
| CN114958774B (zh) * | 2022-05-08 | 2023-10-27 | 中国医学科学院医学生物学研究所 | 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| IL89857A0 (en) | 1988-04-07 | 1989-12-15 | Erba Carlo Spa | Human monoclonal antibodies specifically recognizing rabies virus hybridoma,cells producing them,pharmaceutical compositions containing them and their production |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
-
2001
- 2001-05-04 AT AT01933020T patent/ATE411387T1/de not_active IP Right Cessation
- 2001-05-04 US US09/848,832 patent/US6890532B2/en not_active Expired - Lifetime
- 2001-05-04 EP EP01933020A patent/EP1282703B1/de not_active Expired - Lifetime
- 2001-05-04 DE DE60136174T patent/DE60136174D1/de not_active Expired - Lifetime
- 2001-05-04 RU RU2002133470/13A patent/RU2272809C2/ru not_active IP Right Cessation
- 2001-05-04 WO PCT/US2001/014468 patent/WO2001088132A2/en active Search and Examination
- 2001-05-04 CA CA2419148A patent/CA2419148C/en not_active Expired - Fee Related
- 2001-05-04 JP JP2001584514A patent/JP4819285B2/ja not_active Expired - Fee Related
- 2001-05-04 IL IL152825A patent/IL152825A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL152825A0 (en) | 2003-06-24 |
| EP1282703B1 (de) | 2008-10-15 |
| US20030165507A1 (en) | 2003-09-04 |
| JP2004528803A (ja) | 2004-09-24 |
| CA2419148A1 (en) | 2001-11-22 |
| CA2419148C (en) | 2011-07-12 |
| WO2001088132A3 (en) | 2002-07-18 |
| WO2001088132A2 (en) | 2001-11-22 |
| EP1282703A2 (de) | 2003-02-12 |
| JP4819285B2 (ja) | 2011-11-24 |
| DE60136174D1 (de) | 2008-11-27 |
| RU2272809C2 (ru) | 2006-03-27 |
| IL152825A (en) | 2009-07-20 |
| US6890532B2 (en) | 2005-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE411387T1 (de) | Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren | |
| HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| DK1578936T3 (da) | Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| LU92710I2 (fr) | Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) | |
| CA2469833A1 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
| NZ619953A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
| DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
| DK1503794T3 (da) | Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer | |
| DE60207194D1 (de) | Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens | |
| ATE492563T1 (de) | Vollständige humane monoklonale antikörper gegen il-13 | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| BR0316758A (pt) | Vacinas baseadas em levedura como imunoterapia | |
| ATE395930T1 (de) | Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene | |
| HRP20090527T1 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| ATE288502T1 (de) | Gezieltes antikörper-verfahren | |
| NO20031218L (no) | Kombinasjonsterapi for behandling av autoimmunsykdommer ved anvendelse av B-cellereduserende immunregulerende antistoff kombinasjon | |
| HUP0100794A1 (hu) | Új eljárás humán antigén elleni receptorok előállítására, és azok alkalmazása | |
| WO2003039470A3 (en) | Polyvalent immunogen of hiv | |
| CY1105549T1 (el) | Καινουργια μεθοδος θεραπειας | |
| DE69005908D1 (de) | Monoklonale Antikörper zur Behandlung nach einem Kontakt mit Tollwutvirus. | |
| DE60222296D1 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
| HUP0300142A2 (hu) | Humán LDL-receptorra specifikus monoklonális ellenanyagok, előállításuk és alkalmazásuk | |
| DE60231475D1 (de) | Materialien und methoden zur behandlung von hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |